Baidu
map

PLoS One:过敏性鼻炎和睡眠相关性分析

2020-02-28 AlexYang MedSci原创

最近,有研究人员通过系统性的回顾和元分析调查了过敏性鼻炎和睡眠时间和睡眠损伤之间的相关性。研究包括了2019年8月之前的观察性研究,来源于PubMed、Embase和CINAHL的数据库英文文献。研究人员总共搜索到了2544个研究记录,并排除了914个重复的记录;在筛选了题目和摘要后又移除了1452个记录,全文筛选后排出了151个记录。因此,最后元分析中包括了27篇文章。研究总包涉及了240706

最近,有研究人员通过系统性的回顾和元分析调查了过敏性鼻炎和睡眠时间和睡眠损伤之间的相关性。

研究包括了2019年8月之前的观察性研究,来源于PubMed、Embase和CINAHL的数据库英文文献。研究人员总共搜索到了2544个研究记录,并排除了914个重复的记录;在筛选了题目和摘要后又移除了1452个记录,全文筛选后排出了151个记录。因此,最后元分析中包括了27篇文章。研究总包涉及了240706026名患者(19444043名患有过敏性鼻炎)。分析发现,睡眠持续时间在过敏性鼻炎和对照组之间没有显著的差异。过敏性鼻炎患者表现出了显著更高的睡眠质量评分、睡眠障碍得分和睡眠潜伏期得分;但是睡眠药物的使用频率更高,睡眠效率更低。OR(风险比)调整后元分析表明了过敏性鼻炎与夜间功能障碍有关,包括失眠、夜遗尿、睡眠不安、睡眠呼吸障碍、阻塞性睡眠呼吸暂停和打鼾。同时,风险比调整后元分析还表明了过敏性鼻炎与日间功能障碍相关,包括起床困难、日间嗜睡、早晨头痛和安眠药使用。证据总的质量为低到非常低,因此这些结果仍需进一步验证。

最后,研究人员指出,他们的研究阐释了AR与睡眠质量之间存在显著的额相关性。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047232, encodeId=368a204e232f8, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Mar 11 18:06:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837800, encodeId=82a9183e800d6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 30 23:06:00 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790384, encodeId=fc891e90384ff, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu May 07 17:06:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523641, encodeId=3840152364106, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sun Mar 01 07:06:00 CST 2020, time=2020-03-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047232, encodeId=368a204e232f8, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Mar 11 18:06:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837800, encodeId=82a9183e800d6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 30 23:06:00 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790384, encodeId=fc891e90384ff, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu May 07 17:06:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523641, encodeId=3840152364106, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sun Mar 01 07:06:00 CST 2020, time=2020-03-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047232, encodeId=368a204e232f8, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Mar 11 18:06:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837800, encodeId=82a9183e800d6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 30 23:06:00 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790384, encodeId=fc891e90384ff, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu May 07 17:06:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523641, encodeId=3840152364106, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sun Mar 01 07:06:00 CST 2020, time=2020-03-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047232, encodeId=368a204e232f8, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Mar 11 18:06:00 CST 2020, time=2020-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837800, encodeId=82a9183e800d6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jan 30 23:06:00 CST 2021, time=2021-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1790384, encodeId=fc891e90384ff, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Thu May 07 17:06:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523641, encodeId=3840152364106, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Sun Mar 01 07:06:00 CST 2020, time=2020-03-01, status=1, ipAttribution=)]

相关资讯

盘点:近期鼻炎进展

鼻炎即鼻腔炎性疾病,是病毒、细菌、变应原、各种理化因子以及某些全身性疾病引起的鼻腔黏膜的炎症。鼻炎的主要病理改变是鼻腔黏膜充血、肿胀、渗出、增生、萎缩或坏死等。梅斯医学小编整理了近期鼻炎的研究进展,与大家一起分享学习!【1】J Allergy Clin Immunol Pract:鼻一氧化氮在过敏性鼻炎诊断中的使用研究 鼻NO(nNO)已经在患有鼻息肉或者不患有鼻息肉的慢性鼻窦炎患者

Ear Nose Throat J:药物治疗结合心理干预对持续性中重度过敏性鼻炎患者的心理状况改善情况分析

最近,有研究人员调查了药物治疗结合精神障碍的心理干预对出行中重度过敏性鼻炎患者的治疗情况。研究包括了60名患有持续性中重度且符合研究要求的过敏性鼻炎的患者,并随机分成2个小组:对照组和试验组。对照组只进行药物治疗,试验组在进行相同的药物治疗下结合心理干预治疗。研究发现,对照组的治疗后焦虑自评量表(SAS)和抑郁自评量表(SDS)评分要比治疗前更低,且差异统计学显著。相似的,试验组SAS和SDS评分

盘点:近期鼻炎机制进展

【1】Biol Pharm Bull:过敏性鼻炎中T细胞介导的鼻高反应性 过敏性鼻炎患者承受着各种各样的症状,比如打喷嚏、流鼻涕和鼻塞。随着疾病严重度和慢性进展,鼻高反应性(NHR)能够在这些患者产生和发展。最近,有研究人员在开发一个小鼠过敏性鼻炎模型中,发现了免疫小鼠在进行重复的鼻抗原挑战时能够发展为NHR。通过使用遗传修饰小鼠和一个原始开发的T细胞转移小鼠模型,研究人员确认了NH

J Allergy Clin Immun:鼻炎有救了!研究发现慢性鼻窦炎的治疗靶点

大阪大学的研究人员近日研究了semaphorin蛋白的活性,这是一种细胞表面分子,参与了神经系统的信号传统和免疫分析。他们发现,semaphorin蛋白促进了ECRS患者的过敏反应和鼻息肉的发展。

Eur Arch Otorhinolaryngol:非传染性鼻炎与早发COPD具有更强的相关性

慢性阻塞性肺病(COPD)与一些并发症相关,非传染性鼻炎(NIR)已经成为了一种新的并发症。最近,有研究人员确定了之前一个多中心群体研究报道的NIR与COPD之间的相关性,并调查了上述相关性随着时间变化的情况,即比较了早发与晚发COPD与NIR的相关性情况。他们的研究属于欧盟呼吸健康调查(ECRHS)的一部分。群体为来自欧洲25个中心的随机成年人群体和一个来自于澳大利亚的群体,并进行呼吸量测定和呼

Allergy:青蒿素舌下免疫疗法治疗季节过敏性鼻炎试验

青蒿素是中国北方季节过敏性鼻炎(SAR)的一种重要秋季花粉过敏原。目前,还没有研究调查青蒿素过敏原免疫治疗情况。最近,有研究人员调查了青蒿素舌下免疫治疗(SLIT)的疗效和潜在机制。研究是一个随机、双盲和安慰剂对照III期临床试验,包括了71名SAR患者;并随机分配到青蒿提取物SLIT治疗组(n=47)或者安慰剂组(n=24),治疗进行的时间为32周。研究发现,在第一次花粉峰值阶段(1st PPP

Baidu
map
Baidu
map
Baidu
map